Topic index N ~ Z
A detailed list of topics on follicular lymphoma is covered here:
- new developments in epigenetics
- diagnostic and treatment information including information on new drugs
- scientifically supported natural (lifestyle) strategies applicable by follicular lymphoma survivors.
Upon completion of the registration process and becoming a member you will have access to the material listed here.
Items in red are considered highest priority.
N
Nanotechnology
- 2013 research using nanotechnology to knock out aggressive breast cancer tumors, November 2013 Newsletter, p. 17
- Research on the use of nanotechnology for gene remediation in brain cancer, November 2013 Newsletter, p. 17
- Used in early detection of cancer, October 2009 Newsletter, p. 17
NF-Kappa B pathway
- Berries down-regulate NF Kappa B, October 2009 Newsletter, p. 16-17
- Experimental drugs targeting NF Kappa B pathway, October 2009 Newsletter, p. 17-18
- NF-Kappa B pathway, high sugar intake, and inflammation, February 2008 Newsletter, p. 7
- NF-Kappa B pathway and tocotrienols, January 2008 Newsletter, p. 17-18
Night Sweats, November 2010 Newsletter, p. 14-15
Nutrients (from foods), June 2005 Newsletter, p. 9-11
Nutritional Genomics, February 2005 Newsletter, p. 7-10
O
Omega 6:3 ratio, Article #11, p. 12
Oncogenes, August 2015 Newsletter, p. 8-11
Oranges, Article #3, p. 45-46
Organic Foods, August 2014 Newsletter, p. 21-23
Organochlorines
- As a risk factor for lymphoma, Article #11, p.8; Article #3, p. 67-68; October 2007 Newsletter, p. 8-9
- Risk factors associated with chlorinated water, April 2012 Newsletter, p. 16-17; April 2009 Newsletter, p. 8-9
- Troclosan in soaps interacting with chlorinated water, June 2005 Newsletter, p. 11-13
Ornish, Dr. Dean
- “With Thanks, Respect and Hope”, April 2011 Newsletter, p. 7
- Breakthrough research on epigenetics and prostate cancer, Article #10, p. 4-6; June 2008 Newsletter, p. 3-6
- Need for fNHL research on lifestyle changes and epigenetics patterned on Ornish’s prostate cancer research, February 2013 Newsletter, p. 17-20; March 2011 Newsletter, p. 18-20; September 2010 Newsletter, p. 11-13
Oxygenation, July 2013 Newsletter, p. 11-13
Oxytocin, Article #3, p.73
P
PACE, Article #6, p.27
Paradigm Shift (in understanding and treating fNHL), August 2015 Newsletter (entire); October 2014 Newsletter, p. 4-5; Article #10, p. 3-4; Article #2, p. 4-9; March 2014 Newsletter, p. 10-11; April 2006 Newsletter, p. 5-9; December 2005 Newsletter, p. 5-7
Paraneoplastic Syndrome, Article #3, p.62-63; November 2010 Newsletter, p. 15-16
PCR (R-PCR), January 2009 Newsletter, p. 4-5.
PEP-C April 2008 Newsletter, p. 9-10
Pesticides (see Herbicides and Pesticides)
PET scans
- Research on high frequency of false positive PET scans in regard to diagnosis of relapsed lymphoma, Article #5, p. 30-31; June 2011 Newsletter, p. 18-20
- Risks of over-exposure to radiation, Article #5, p. 28-31; Article #10, p. 23; May 2015 Newsletter, p. 12-16; January 2010, p. 14-17
- Limitations of PET scans, Article #5, p. 30-31; September 2007 Newsletter, p. 5-7; May 2005 Newsletter, p. 10
Pidilizumab (CT-011)
- “Pidilizumab (CT-011) Looks Very Promising (Better then Ibrutinib?)”, April 2014 Newsletter, p. 13-15
PI3K/Akt Signaling Pathway
- PI3K (delta) and Idelalisib, December 2013 Newsletter, p. 15-18
- Quercetin as a dual-specific activator of mTOR and the PI3K/Akt signaling pathway, November 2013 Newsletter, p. 13-15
- PI3K as a target for new drugs to treat follicular lymphoma, November 2013 Newsletter, p. 15
Planning Horizon (also see Long-Term Survival)
- “Our Four Groups of Members: Who They Are and What They Need”, September 2011 Newsletter, p. 3-17
- “Grateful for 25 Years Since Diagnosis: The Key Strategic Factors”, July 2013 Newsletter, p.2-7
- “From Knowledge to Success … 9 Essential Steps in Managing fNHL”, March 2011 Newsletter, p. 3-9
- “The Five Key Things That Got Me This Far”, January 2011 Newsletter, p. 3-9
- “Cracking the Code for Entering the Thrive Zone”, December 2010 Newsletter, p. 4-6
- “Strategic Requirements for the Thrive Zone”, December 2010 Newsletter, p. 6-8
- Factors to consider in planning for 20 ++ years of survival, February 2010 Newsletter, p. 2-6; November 2009 Newsletter, p. 3-5; November 2006 Newsletter, p. 5-9
- Planning for transformation: Most important considerations, Article #6, p.16; January 2009 Newsletter, p. 3-4
- An overall strategy for managing fNHL for long-term success, February 2009 Newsletter, p. 2-6
- “40 Must Know Things Learned After 22 Years — Especially Important for the Newly Diagnosed”, July 2010 Newsletter, p. 4-10
- ” Maintaining a Clinical Remission”, September 2010 Newsletter, p. 6-9
- Three phases in the long-term management of follicular lymphoma, November 2007 Newsletter, p. 3-6
- Significance of relapse in long-term management and survival, September 2007 Newsletter, p. 4-5
Plastics, February 2010 Newsletter, p. 10-11; February 2008 Newsletter, p. 10-11
Phytochemicals
- Suppression of cell-signalling pathways, October 2006 Newsletter, p. 8-9; December 2004 Newsletter, p. 9-10
Pomegranate Juice, Article #3, p. 50; July 2006 Newsletter, p. 5
Prednisone, March 2010 Newsletter, p. 17-18
Prevention
- Lifestyle strategies and cancer prevention, Article #2, p. 4-9; February 2014 Newsletter, p. 11-13
Probiotics, Article #11, p. 13
Problematic Nodes, Article #6, p. 8-9
Progression-Free Survival, April 2009 Newsletter, p. 7-8
Protein Powder Supplements
- Protein powder supplements are foods to avoid for cancer patients, Article #10, p. 26-27; Article #11, p. 10-11; Article #7, p. 43-44; December 2012 Newsletter, p. 12-13; Article #3, p. 54
- Protein powders, glutamine, and transformation, Article #4, p.14
- Avoidance advised concerning whey protein, Article #10, p. 26-27; Article #3, p. 54; June 2012 Newsletter, p. 17-19
PubMed, May 2010 Newsletter, p. 18
Pumpkin Seeds, Article #3, p. 40
Psychological Factors and treatment options, Article #1; Article #6; October 2008 Newsletter, p. 7-8
Q
Quercetin
- Epigenetic anti-cancer effects of quercetin, Article #11, p. 13-14; November 2013 Newsletter, p. 13-15
- Quercetin in apples “natural mimic” of many enzyme-based cancer therapies now under development, October 2012 Newsletter, p. 21-22; Article #3, p.45; November 2013 Newsletter, p. 13-15
R
R-Bendamustine (see Bendamustine)
R-CHOP
- Importance of reserving use of R-CHOP for transformation, Article #4, p. 8-9; Article #6, p. 5-8
- Comparison of R-CHOP and R-Bendamustine when used as an initial treatment, Article #7, p. 24-25; August 2011 Newsletter, p. 11-14
- Gene MLH1 status can block response to CHOP, April 2015 Newsletter, p. 7-9
- General information, Article #4, p. 1-9; Article #6, p. 19-20; August 2012 Newsletter, p. 9-10; Article #7, p.11-12
- Critical information on possible shortages of chemotherapy drugs used to treat transformation, December 2010 Newsletter, p. 15-16
- As treatment for transformation, Article #4, p. 8-9
- CHOP and the heart, April 2010 Newsletter, p. 21-23
- R-CHOP as a choice for initial therapy, Article #7, p. 19-20; Article #6, p.19-20.
- Comparative data for R-CHOP and Bendamustine as choice for initial therapy, February 2011 Newsletter, p. 14-17
- Dose-dense R-CHOP, March 2005 Newsletter, p. 6-8
- Using Co-Enzyme Q-10 when receiving CHOP, October 2010 Newsletter, p.21, Article #8, p.9; March 2009 Newsletter, p. 10
- R-CVP vs. R-CHOP with managerial implications, April 2009 Newsletter, p. 2-5
- Doxorubicin caution, January 2008 Newsletter, p. 18-19
- ECG suggested before treatment with R-CHOP, February 2011 Newsletter, p. 19-20
- Increased potential of R-CHOP to markedly increase survival rates when reserved for probable event of transformation, August 2008 Newsletter, p. 7-8
- Valsartan to prevent chronic doxorubicin-induced toxicity, April 2007 Newsletter, p. 8-9
R-CP, Article #6, p.27
R-CVP
- General information, Article #6, p.17-18, August 2012 Newsletter, p. 10-11
- As choice for initial therapy, Article #6, p.17-18.
- R-CVP vs. R-CHOP with managerial implications, April 2009 Newsletter, p. 2-5
R-CyP, February 2008 Newsletter, p. 2-5; August 2007 Newsletter, p. 7-8
R-DHAOx, January 2010 Newsletter, p. 17-19
R-ESHAP, Article #6, p. 26
R-FC, Article #6, p. 16; July 2007 Newsletter, p. 10-11
R-FND, Article #6, p. 16;
R-GDP
- Article #6, p. 26, Article #4, p.9-10; August 2012 Newsletter, p. 14
- “The Merits of R-GDP (New Research plus Personal Experience)”, November 2014 Newsletter, p. 21-22
R-GCVP, Article #4, p. 10-11; March 2014 Newsletter, p. 8-9
R-ICE, Article #6, p. 26
R-PCR (PCR), Article #6, p.27; January 2009 Newsletter, p. 4-5.
Radiation
- “Low Dose Radiation Update with a Detailed Personal Account”, December 2013 Newsletter, p. 5-7
- General discussion of research pertaining to the use of low dose field radiation therapy (LDIFRT) in treating fNHL, Article #6, p. 20-21; August 2012 Newsletter, p. 14; October 2011 Newsletter, p. 12-13; January 2011 Newsletter, p. 12-14
- Lymphoma in the eye region and radiation treatments, September 2014 Newsletter, p. 11-12
- “Caution re Eight or More CT Scans Plus PET”, May 2015 Newsletter, p. 12-16
- Tocotrienols and their potential for mediating radiation damage, July 2013 Newsletter, p. 19-22.
- Effectiveness of radiation in treating fNHL, September 2010 Newsletter, p. 5-6
- Radiation for treatment of nodes of cosmetic concern, Article #7, p. 35-36
- Radiation and early stage lymphoma, June 2009 Newsletter, p. 14-15
- Radiation treatment of “limited stage” fNHL patients associated with possible increase in risk for transformation, December 2012 Newsletter, p. 16-17
- Overview of use in the treatment of fNHL, April 2009 Newsletter, p. 5-6
- Intensity Modulated Radiation Therapy (IMRT), October 2011 Newsletter, p. 12-13; August 2007 Newsletter, p. 10
Rainbow Salad, Article #3, p.50
Raspberries, Article #3, p. 41
Red Palm Oil
- Epigenetic anti-cancer effects of tocotrienols in red palm oil, Article #11, p. 17, February 2016 Newsletter, p. 21; July 2013 Newsletter, p. 19-22; February 2013 Newsletter, p. 9-10; Article #3, p.43; March 2011 Newsletter, p. 12-13; April 2009 Newsletter, p.12-14; June 2007 Newsletter, p.5; April 2007 Newsletter, p. 9-10
- Red palm oil may help to counteract negative effects of radiation, May 2015 Newsletter, p. 14-16
- Red palm oil and gene p53, June 2015 Newsletter, p. 21-22
Relapse
- “Let’s Take on the Challenge of Relapse”, October 2019 Newsletter, p. 6-9
- How to prevent or delay relapse after first treatment, October 2015 Newsletter, p. 19-23
- Treatment options in the event of relapse after treatment with R-Benda, October 2015 Newsletter, p. 13-19
- Guidelines for when to treat relapse situations, Article #6, p. 10-11; August 2013 Newsletter, p. 19-21
- September 2007 Newsletter, p. 4-5
Reno, Jamie, review of book, “Hope begins in the dark: Fifty lymphoma survivors tell their exclusive life stories”, February 2008 Newsletter, p. 15
Restless Leg Syndrome, November 2010 Newsletter, p. 15, November 2009 Newsletter, p. 18-19
Resveratrol
- Epigenetic anti-cancer effects of resveratrol, Article #11, p. 14
- New, reduced dosage suggested for daily supplementation with trans-resveratrol, May 2012 Newsletter, p. 15-16; Article #3, 38-39
- How to calculate the “trans” component in resveratrol supplements and caution re deceptive labeling of resveratrol supplements, November 2011 Newsletter, p. 16-17
- Resveratrol is on the “A” Team, Article #3, p. 38-39; March 2010 Newsletter, p.16-17
- Suggestions for ingesting resveratrol, Article #3, p. 38-39; April 2011 Newsletter, p. 21-22, December 2010 Newsletter, p. 11
- Research updates on resveratrol, February 2013 Newsletter, p. 12-13; December 2010 Newsletter, p. 10-12
- Resveratrol bioavailability, July 2009 Newsletter, p. 14-15
- Research on safe dosage, August 2010 Newsletter, p. 17
- Effect on mitochondria, May 2011 Newsletter, p. 13-15, November 2010 Newsletter, p. 10, June 2010 Newsletter, p. 6-7, July 2010 Newsletter, p. 13-15, September 2010 Newsletter, p. 8; Article #3, p. 38
- How to read supplement labels to determine the correct dosage for trans-resveratrol, July 2010 Newsletter, p. 14-15
- Resveratrol ability to block cancer cell telomerase, March 2010 Newsletter, p. 6
- Resveratrol, the bcl-6 pathway, and the annoucement of a “new class” of lymphoma drugs in April 2010, June 2010 Newsletter, p. 6-7
- Summary of research studies on anti-cancer effects of resveratrol, June 2009 Newsletter, p. 11-14
- Research on resveratrol and transformed fNHL cells, Article #4, p. 24; June 2012 Newsletter, p. 14-16; June 2009 Newsletter, p. 11-12
- Precautions on dosing with high-dosage trans-resveratrol, June 2009 Newsletter, p. 13-14
Retinoids, February 2016 Newsletter, p. 14-22
Revlimid (Lenalinomide)
- General information, Article #6, p. 29; August 2012 Newsletter, p. 14-15; May 2008 Newsletter, p. 14
Rice Bran Oil, Article #3, p. 42
Rituximab (also see Maintenance Rituximab)
- General information, Article #6, p. 13; August 2012 Newsletter, p. 15-17; “Rituximab … Expert Balanced Opinions .. a Must Read”, March 2011 Newsletter, p. 9-10; Article #6, p. 2-4
- Important results from RESORT Trial, January 2012 Newsletter, p. 10-15; December 2011 Newsletter, p. 3-7
- Maintenance rituximab (MR) , November 2014 Newsletter, p. 5-6; October 2014 Newsletter, p. 15-17; Article #6, p. 18-19; Article #7, p. 20-22; “More Cautions re Maintenance Rituximab”, June 2014 Newsletter, p. 15-17; “Update to September 2012”, September 2012 Newsletter, p. 3-8
- “End of Rituximab Maintenance for Low-Tumor Burden Follicular Lymphoma”, November 2014 Newsletter, p. 5-6
- No overall survival advantage found between watchful waiting, chemoimmunotherapy, and initial treatment with rituximab monotherapy, February 2016 Newsletter, p. 4-6
- Gene CDKN2A status predicts overall survival time for patients treated with rituximab, April 2015 Newsletter, p. 5-7
- “Strategies to Stay Healthy While on Maintenance Rituximab”, March 2015 Newsletter, p. 16
- Rituximab and beta glucans, Article #8, p. 8-9
- Research study finds prolonged use of rituximab heightens risk of suppressed long-term immunity, October 2011 Newsletter, p. 9-12
- Rituximab and exercise, July 2008 Newsletter, p. 11
- Rituximab and colony growth stimulating factors, December 2004 Newsletter, p. 8-9
- Rituximab and risk of progressive multifocal leukoencephalopathy (PML), July 2009 Newsletter, p. 4-8
- “Rituximab, what’s known, what isn’t”, May 2009 Newsletter, p. 5-7
- Rituximab and immunity, March 2009 Newsletter, p. 15-16
- Rituximab resistance and transformation, February 2010 Newsletter, p. 9-10
- Chlorambucil and rituximab, June 2007 Newsletter, p. 9-10
Root Canals, May 2008 Newsletter, p. 7-8
Rosenberg, Dr. Saul
- Dr. Rosenberg’s research and its implications for explaining spontaneous regression, February 2014 Newsletter, p. 2; 5-9
- Dr. Rosenberg’s research on watch and wait, Article #5, p. 12-14; March 2008 Newsletter, p. 3-6; Article #2, 24-29
Roundup (Glyphosate)
- Roundup weedkiller classified by the World Health Organization as a “probable carcinogen” linked to an increased risk of non-Hodgkin lymphoma, May 2015 Newsletter, p. 16-19
S
SAD (Seasonal Affective Disorder) , December 2015 Newsletter, p. 21-22
Salmon (Wild), Article #3, p. 47-49
Salmon Oil (Wild)
- Epigenetic anti-cancer effects of wild salmon oil, September 2015 Newsletter, p. 21-22; Article #11, p. 11
- Article #3, p. 41-42
Scans
- Vitamin E tocotrienols found to reduce damage from radiation scanning, Article #5, p. 32-33; July 2013 Newsletter, p. 19-22
- PET scans and false positive results, Article #5, p. 30-31
- Radiation dangers, May 2015 Newsletter, p. 12-16; April 2011 Newsletter, p. 7-10, January 2010 Newsletter, p. 14-17
- “Caution re Eight or More CT Scans Plus PET”, May 2015 Newsletter, p. 12-16 (see correction to 4 or more scans in June 2015 Newsletter, p.17-19)
- Treatment decisions and scans, Article #7, p. 9-10
- Using MRIs and ultrasounds for routine scanning, Article #5, p. 31-32
- Combined PET and CT scanning, May 2015 Newsletter, p. 12-16; Article #5, p. 30-31
- Radiation exposure of CT scans, May 2015 Newsletter, p. 12-16; October 2009 Newsletter, p. 13-16; November 2007 Newsletter, p. 14-16; January 2006 Newsletter, p. 6-7
- Recommendations for CT scan frequency, December 2013 Newsletter, p. 19-22; March 2009 Newsletter, p. 14
- Secondary Cancers, May 2009 Newsletter, p. 12
Selenium
- Epigenetic anti-cancer effects of selenium, Article #11, p. 14-15
- Selenium as a daily supplement, Article #3, p. 42
- Need to be take with Vitamin E, Article #3, p. 43; November 2008 Newsletter, p. 9-10
- Gene P53 and selenium, February 2013 Newsletter, p. 9-10; May 2011 Newsletter, p. 15-16, Article #3, p. 42; November 2008 Newsletter, p. 9
- Brazil nuts and selenium supplements — actual selenium content, November 2008 Newsletter, p.9
Seyfried, Dr. Thomas, Article #11, p. 10; November 2012 Newsletter, p. 5-7
Sinus Congestion
- Polysporin, bacitracin and sinus infection, December 2015 Newsletter, p. 23-24; January 2012 Newsletter, p. 23
- Low IgA levels and chronic sinus infection, November 2011 Newsletter, p. 5
- Managing nasal infection and sinus congestion with essential oil vapors, Article #3, p. 63-64; How to instructions for using steam vapors and essential oils to help clear sinus passages and prevent infection, December 2010 Newsletter, p. 16-18
- Penetrating nasal passageways with tea tree oil and anise, November 2009 Newsletter, p.11-14
- Adding oil of oregano to tea tree oil and anise oil mixture, February 2010 Newsletter, p. 16
Skin Conditions
- Itchy skin and skin rashes, November 2010 Newsletter, p. 15-16
- Staph infections and how to prevent them, June 2012 Newsletter, p. 22-23
Sleep
- Epigenetic anti-cancer effects of quality sleep, Article #10, p. 19-21; Article #11, p. 15
- Importance of quality sleep, December 2015 Newsletter, p. 26-27; August 2015 Newsletter, p. 19-21; June 2015 Newsletter, p. 11-13: January 2013 Newsletter, p. 16-17; Article #3, p. 29-35; March 2011 Newsletter, p. 21-22
- “Sleep Deprivation Alters Genetic Expression …. Latest Research”, March 2013 Newsletter, p. 8
- Importance of totally dark room and sleep mask, Article #3, p. 31; June 2010 Newsletter, p. 17
- Poor sleep linked to dietary fat and sugar, February 2016 Newletter, p. 21-22
- Quality sleep and chronic stress, Article #10, p. 19-20; Article #3, p. 32-35; February 2005 Newsletter, p. 10-11
- Sleep and melatonin, Article #3, p. 30-32; September 2006 Newsletter, p. 11-12; March 2006 Newsletter, p. 9-12
- Quality sleep, nighttime darkness, and breast cancer study, March 2008 Newsletter, p. 15-16
- Sleep and the ROS (reactive oxygen species) cascade, Article #3, p. 33-34; November 2007 Newsletter, p. 9-11; June 2007 Newsletter, p. 16-17; December 2006 Newsletter, p. 9-11
- Sleep and immunity, May 2005 Newsletter, p. 10-12
- Natural technique for reinforcing the “hormone twins” (Vitamin D and melatonin) for a better night’s sleep, Article #3, p. 31-32; July 2008 Newsletter, p. 8-10
Shiitake Mushrooms, October 2019 Newsletter, p. 5-6
Spontaneous (Natural) Regression (SR)
- Dr. Saul Rosenberg’s research on “watch and wait” and how it helps us understand spontaneous (natural) regression, February 2014 Newsletter, p. 5-9
- Epigenetics, follicular lymphoma, and natural regression, Article #11, p. 20-23
- “Updating What We Know About Spontaneous (Natural) Regression”, February 2014 Newsletter, p. 8-11
- “Must know” details about SR for follicular patients, Article #10, p. 1-10; October 2009 Newsletter, p. 3-7; April 2006 Newsletter, p. 9-11
- Frequent hiking in the sun and spontaneous regression, Article #10, p. 8-10; July 2013 Newsletter, p. 7-15
- “A Real Life Example of an Epigenetic Intervention Leading to Spontaneous Regression”, Article #10, p. 8-10
- Spontaneous regression as an indicator of long-term survival, March 2011 Newsletter, p. 20-21; August 2008 Newsletter, p. 17-18
- Reactive oxygen species (ROS) cascade and spontaneous regression, November 2007 Newsletter, p. 9-11
- Personal reflections on SR, October 2005 Newsletter, p. 2-4
Stages of Follicular Lymphoma, Article #5, p. 6-8; Article #2, p.11-13; Article #7, p. 7-8
STDs, December 2009 Newsletter, p. 17-18
Stem Cells
- 2013 research explores the use of stem cells in a gene transfer method that targets tumor cells, November 2013 Newsletter, p. 16-17
- Malignant stem cells, April 2007 Newsletter, p. 6-8; December 2006 Newsletter, p. 2-5
Stem Cell Transplants (SCTs)
- Latest SCT research results (August 2013), September 2013 Newsletter, p. 13-17
- SCTs and transformation, Article #4, p. 12; 20-22
- Comparative data on relative effectiveness of chemotherapy, auto SCTs and allo SCTs in treating transformation in fNHL patients, April 2013, p. 17-20
- New research on rituximab resistance and SCT outcomes, June 2014 Newsletter, p. 15-17
- General information, Article #6, p. 21-24; Article #7, p. 29-31; August 2012 Newsletter, p. 17-18
- Latest research on stem cell transplants and fNHL, including overall survival findings and key information on genetic factors, March 2013 Newsletter, p. 8-13
- Study shows patients with pre-transplant deficient levels of Vitamin D have a much greater risk of developing graft vs. host disease in allogenetic stem cell transplants, October 2012 Newsletter, p. 14-17
- New genetic research regarding diffuse components in transformation and relevance to an SCT, November 2011 Newsletter, p. 10-11
- Autologous SCTs and the presence of the c-Myc gene in pathology reports, October 2011 Newsletter, p. 9-11
- Web link to Greg Dafoe’s website Non-Hodgkin’s Lymphoma Cyberfamily,for high quality research and insights on fNHL and SCTs, January 2008 Newsletter, p. 9
- Graft vs. host disease (GVHD) and SCTs, January 2008 Newsletter, p. 10-12
- Mortality following an autologous SCT, August 2009 Newsletter, p. 11-12
- Relapse after an autologous SCT, March 2009 Newsletter, p. 14-15
- Mozobil and autologous SCTs, March 2009 Newsletter, p.15; August 2007 Newsletter, p. 6-7
- SCT mortality statistics, January 2009 Newsletter, p. 7-8
- Autologous SCTs and in-vivo purging, April 2008 Newsletter, p. 8-9
- Autologous SCTs and prognostic indicators for long-term survival, February 2008 Newsletter, p.15
- Second malignancies and SCTs, April 2005 Newsletter, p. 10-12
- Harvesting stem cells, March 2008 Newsletter, p. 8-9
- SCTs and older patients, July 2008 Newsletter, p. 13
- Autologous SCTs and fNHL grade, November 2007 Newsletter, p. 18
- Studies on long-term effectiveness of autologous SCTs, August 2007 Newsletter, p. 5-6; October 2006 Newsletter, p.17-20; March 2005 Newsletter, p. 8-11
- Chlorambucil and SCTs, April 2007 Newsletter, p. 6
- Harvesting healthy stems cells, December 2006 Newsletter, p. 5-7
- Allogeneic SCTs, January 2005 Newsletter, p. 6-8
Steroids, January 2009 Newsletter, p. 10-11
Stress
- “How Stress is Associated with Follicular Lymphoma”, December 2014 Newsletter, p. 17-23
- Potentially harmful epigenetic effects of stress for cancer patients, Article #10, p. 21-22; Article #11, p. 16
- Cortisol, stress and cancer, Article #10, p. 21-22; Article #11, p. 14-15
- April 2012 Newsletter, p. 14-16; Article #3, p. 32-33; June 2007 Newsletter, p. 15-16; December 2005 Newsletter, p. 7-8
- “Medical Aspects of Stress and Cancer”, April 2013 Newsletter, p. 22-24
- Stress and sleep, Article #3, p.35-37; July 2010 Newsletter, p. 10-13
Sulforaphane
- Epigenetic anticancer effects of sulforaphane, Article #10, p. 24-25; Article #11, p. 16-17
- Sulforaphane in brocolli, brocolli sprouts, and brussels sprouts, a natural histone deacetylase (HDAC) inhibitor, February 2013 Newsletter, p. 5-6; April 2015 Newsletter, p.16-17; April 2012 Newsletter, p. 12-13; July 2011 Newsletter, p. 6-10; November 2010 Newsletter, p. 8-9
Sugar
- “Sugar, Glutamine, and Cancer Genes”, April 2013 Newsletter, p. 3-7
- Dietary challenges in reducing sugar in the diet, October 2014 Newsletter, p. 13-15; January 2013 Newsletter, p. 5-9
- Research demonstrates sugar and glutamine intakes are inter-dependent in fueling cancer cell growth, February 2012 Newsletter, p. 3-8
- Sugar as risk factor for cancer, Article #10, p. 22-24; Article #11, p. 11; Article # 3, p. 23; March 2012 Newsletter, p. 4-6; February 2011 Newsletter, p. 17; January 2010 Newsletter, p.19-20
- Exercise as a strategy for reducing negative impact of sugar, Article #7, p. 36-37; Article #3, p. 23
- Akt cell signaling pathway, sugar, and cancer, June 2008 Newsletter, p. 6-7
- NF-Kappa B pathway, high sugar intake, and inflammation, February 2008 Newsletter, p.7
Sun exposure (incidence of fNHL), Article #10, p. 15; April 2007 Newsletter, p. 3-4
Sunlight
- Sunlight may be the most potent source of vitamin D, Article #10, p.14-16; Article #11, p. 19
- Residing in latitudes north of 55 degrees N associated with shorter overall survival time for lymphoma survivors, Article #10, p.15; November 2013 Newsletter, p. 15-16
- MIT scientist proposes dietary sulphur intake and sunlight exposure are essential keys to optimal health, November 2011 Newsletter, p. 19-20
- Breast cancer researchers find a combination of both sunlight and supplemental vitamin D is most effective in reducing cancer risk, Article 10, p. 15; March 2013 Newsletter, p. 17-18
Supplement Use
- Avoiding the common error of over supplementation, August 2014 Newsletter, p. 19
- Study finds excessive use of dietary supplements associated with increased cancer risk, May 2015 Newsletter, p. 20-21
- Misuse of supplements can be toxic, Article #7, p. 13-17; March 2014 Newsletter, p. 17-18
- Discussion of wise and unwise use of supplements and pitfalls of promotional diets, Article #7, p. 13-17; November 2011 Newsletter, p. 5-10
- Dangers of over-using antioxidant supplements, Article #7, p. 13-17; December 2009 Newsletter, p.18-19; November 2009 Newsletter, p.15-16; July 2009 Newsletter, p.12-14; May 2008 Newsletter, p.12-13
- Norwegian clinical trial investigates effects of supplementation for fNHL patients with omega 3 fatty acids (fish oil), selenium, garlic, ellagic acid (pomegranate juice), resveratrol/quercetin, green tea, June 2007 Newsletter, p. 16
Survival (see Long-Term Survival)
T
T-Cell Immunotherapy, June 2005 Newsletter, p. 1-3
Targeted Natural Strategies (4P-GRS) for Long-Term Survival (see also Lifestyle Strategies)
- Detailed analysis and research guides to the epigenetic anticancer effects of the 4P-GRS strategies suggested in Article #3: Article #10, Article #11
- Ringleader fNHL genes and enzymes and targeted natural strategies affecting their epigenetic expression, February 2013 Newsletter, p. 2-25
- High tumor microenvironment expression of CD7 and dietary lifestyle factors in fNHL patients linked to increased survival time, December 2012 Newsletter, p. 8-10
- “Living the Natural Strategies Everyday”, August 2011 Newsletter, p. 3-11
- Scientific premises for TNS, Article # 10, p. 9-13; Article #3, p.6-14; Article #11, p. 2-5; 20-24
- The many advantages of using natural strategies to slow cancer progression, Article #10, p. 1-10
- Updated dietary and supplementation strategies, Article #3, p. 35-57; October 2010 Newsletter, p. 8-19
- Importance of Targeted Natural Strategies, March 2007 Newsletter, p. 4-11
- “Jill’s Quick Action Plan”, suggestions to help get quickly “up and running” with 4 pillar lifestyle program presented in Article #3, September 2013 Newsletter, p. 23-24
- Essence of Targeted Natural Strategies (the A Team), March 2008 Newsletter, p. 6-8
- Controversy concerning the use of TNS and fNHL, October 2006, p. 3-8
- Importance of the “before and after” strategies, Article #10, p. 6-7; August 2013 Newsletter, p. 16-18
Telomerase
- Telomerase, telomeres, and cancer cells, June 2007 Newsletter, p. 8-9
- Telomerase key to developing potential cancer breakthrough, March 2010 Newsletter, p.6
Tempo, Discussion of tempo and the “tipping point”, Article #6, p. 9-10
Toxoplasmosis, July 2006 Newsletter, p. 7-8
Toxins (in food) , October 2013 Newsletter, p. 10-13
TP53 Gene
- The potency of gene TP53 in influencing follicular lymphoma progression, November 2015 Newsletter, p. 18-20
Transformation
- Essential information on follicular lymphoma transformation: Article #4
- Important updated information on follicular lymphoma transformation, February 2015 Newsletter, p. 11-18
- SUV uptake values and transformation, February 2015 Newsletter, p. 14-15
- Interpretation of diffuse pattern results in tissue biopsies as it pertains to diagnosing transformation, Article #5, p. 17-19; Article #7, p. 20-24; September 2011 Newsletter, p. 17-18
- Genes associated with follicular lymphoma transformation, Article #4, p. 19-20; June 2014 Newsletter, p. 4-8
- Biopsies and uncertainty re interpretation of pathology results at the time of suspected transformation, Article #4, p. 6-8; Article #5, p. 17-19
- Have I transformed?, Article #4, p. 6-8; Article #7, p. 20-24, March 2014 Newsletter, p. 4-7, July 2007 Newletter, p. 11-14
- Research identifies specific genes associated with transformation, Article #4, p. 19-20; March 2014 Newsletter, p. 7-8
- New chemo treatment R-GCVP developed for patients with heart concerns, Article #4, p. 10-11; March 2014 Newsletter, p. 8-9
- “Localized” transformation and treatment options, Article #5, p. 17-19; Article #7, p. 22-23
- Chemotherapy and transformation, Article #4, p. 8-12; September 2010 Newsletter, p. 3-6
- Understanding transformation, Article #2, p. 29-31; Article #4, p. 1-9; Article #6, p. 5-8; Article #7, p. 20-24; November 2009 Newsletter, p. 5-9; February 2006 Newsletter, p. 2-9
- Rosenberg, Dr. Saul, “Follicular Lymphoma Re-Visited”, March 2008 Newsletter, p. 3-6
- Planning for transformation: most important considerations, Article #6, p.5-8
- Critical information on possible shortage of chemotherapy drugs used to treat transformation, December 2010 Newsletter, p. 15-16
- Major treatment options for transformation, Article #4, p. 8-12
- Elevated LDH and transformation, Article #4, p. 5-6
- Role of gene P53 in transformation, Article #4, p. 24; January 2008 Newsletter, p. 13-14
- Risk of transformation rises 3% per year, November 2008 Newsletter, p.10-11
- Natural strategies to combat transformation, Article #4, p. 24; November 2008 Newsletter, p. 12-13
- Resveratrol and transformation, Article #4, p. 24
- R-CHOP and transformation, Article #7, p. 19-25; Article #4, p.8-9
- Web link to Dr. Zelenetz webcast on transformation, January 2011 Newsletter, p. 20
- PET scans and transformation, Article #4, p.6-7
- “Transformation: A Yes or No Event?”, March 2010 Newsletter, p. 9-11
- B Symptoms and transformation, Article #4, p. 5-6; Article #2, p. 32: Article #3, p. 69-70
- Treatments for second transformation, Article #4, p. 9-10; Article #6, p.26, Article #7, p.23-24
- Biomarkers, predicting overall survival time,and transformation, Article #4, p. 15-16; September 2008 Newsletter, p. 5-6
- Rituximab resistance and transformation, February 2010 Newsletter, p. 9-10
- Research study on resveratrol and transformed fNHL cells, June 2009 Newsletter, p. 11-12
- Prognostic indicators and transformation, Article #4, p. 15-16; November 2006 Newsletter, p. 9-12
- Overall survival and transformation, Article #4, p. 13-15
Treatment-Wellness Spectrum, Article #3, p. 12-13, August 2012 Newsletter, p. 4-5; April 2011 Newsletter, p. 3-4, March 2010 Newsletter, p. 15-16: August 2008 Newsletter, p. 3-5; February 2010 Newsletter, p. 17
Triphala, June 2008 Newsletter, p.10
Tumor Suppressor Genes
- The importance of tumor suppressor genes in holding fNHL in check, August 2015 Newsletter, p. 9-10; 21-23
- Description of tumor suppressor genes, August 2015 Newsletter, p. 8-10
- Animal research finds reactivation of key tumor supressor gene can revert cancer cells to normal tissue, July 2015 Newsletter, p. 17-18
- The importance of tumor suppressor genes in both fNHL growth and natural regression, August 2015 Newsletter (entire)
Turmeric (see curcumin)
Tyrosine Kinase Inhibitors
- Natural inhibitors of tyrosine kinases, Article #11, p. 9-10
- “Clinical Trial Results with New Kinase Drugs Idelalisib and Imbruvica”, January 2014 Newletter, p. 12-16
- Ibrutinib, BTK gene, concerns with immunity, September 2013 Newsletter, p. 3-13
U
V
Vaccines
- Biovax vaccine, August 2012 Newsletter, p. 7-8; August 2009 Newsletter, p.12-13; July 2008 Newsletter, p.14-17; January 2008 Newsletter, p. 5-6; December 2007 Newsletter, p.15-16
- Vaccine novelty, July 2008 Newsletter, p.14-17
- Why cancer vaccines may not work, June 2009 Newsletter, p.17-18; February 2009 Newsletter, p.12; January 2008 Newsletter, p.4-5; May 2005 Newsletter, p. 4-7
- Bendandi vaccine, September 2008 Newsletter, p.16; March 2008 Newsletter, p. 9-10; January 2008 Newsletter, p.6; May 2007 Newsletter, p.2; January 2007 Newsletter, p. 2-5
- Favrille vaccine, June 2008 Newsletter, p.11-12; January 2008 Newsletter, p.5 ; December 2007 Newsletter, p.15
- MyVax vaccine, January 2008 Newsletter, p.2-4; December 2007 Newsletter, p.14-15
- Common terminology used in discussing vaccine therapy, May 2005 Newsletter, p 6-7
Valporic Acid, July 2013 Newsletter, p. 22-23
Vascularization
- Vascularization and fNHL, December 2007 Newsletter, p. 8-9
- Research identifying vascularization as a strong prognostic indicator in regard to transformation and overall survival in fNHL, September 2010 Newsletter, p. 13-14
- Ellagic acid and vascularization, Article #11, p. 7; Article #10, p. 25-26; September 2010 Newsletter, p. 14
Vegetable intake and lymphoma, July 2006 Newsletter, p. 6-7
Vitamin A, December 2015 Newsletter, p. 14-18; April 2015 Newsletter, p. 14-16, February 2016 Newsletter, p. 14-22.
Vitamin B-12, Article #3, p. 43; July 2009 Newsletter, p. 15-16
Vitamin D
- “Effects of Vitamin D on Follicular Lymphoma Survival — Reinforcing the Latest Data”, October 2019 Newsletter, p. 9-12
- Epigenetic anticancer effects of vitamin D, Article #10, p.13-16; Article #11, p. 18-19
- Not optimizing vitamin D is a strategic error for fNHL patients, April 2015 Newsletter, p. 18-20
- Low vitamin D levels in fNHL patients found to be “surprisingly strong” prognostic indicators for overall survival (OS) outcomes, May 2015 Newsletter, p. 4-6; Article #10, p. 14; December 2012 Newsletter, p. 6-8
- “The Sensible Management of Vitamin D”, November 2011 Newsletter, p. 13-16
- Epigenetics, follicular lymphoma, natural regression, and the Myc gene, Article #11, p. 18-19
- Ensuring a year-round optimum level of Vitamin D, Article #7, p. 11-13; Article #3, p. 16-22
- Using vitamin D as a prognostic indicator of survival, Article #2, p. 29-31
- Vitamin D testing information, April 2011 Newsletter, p. 21
- Clinical research studies on cancer and Vitamin D levels
- Vitamin D follicular lymphoma study reports low serum vitamin D levels associated with inferior overall survival, May 2015 Newsletter, p. 4-6
- Summary of 2012 vitamin D research study from Norway, “best yet” for associations with overall survival in lymphoma patients, April 2013, p. 10-12
- Vitamin D found to inhibit the production and function of protein cMyc, which helps to drive cancer cell division, February 2013 Newsletter, p. 6-8
- Breast cancer researchers find a combination of both sunlight and supplemental vitamin D is most effective in reducing cancer risk, March 2013 Newsletter, p.17-18
- “Summarizing the latest research”, February 2012 Newsletter, p. 10-18
- Cancer patients have lower vitamin D levels, January 2012 Newsletter, p. 10-13
- Clinical trial results show insufficient Vitamin D levels in CLL patients linked to cancer progression and survival times, December 2010 Newsletter, p. 9
- Research shows vitamin D levels declining in general population, March 2012 Newsletter, p. 13-14
- Study finds pre-transplant deficient levels of Vitamin D have a negative impact on outcomes of allogenetic stem cell transplants, October 2012 Newsletter, p. 14-17
- December 2009 Newsletter, p.13-15
- New model of cancer development cites low Vitamin D, June 2009 Newsletter, p. 9-10
- Vitamin D and depression, October 2008 Newsletter, p.12
- Breast cancer and low levels of Vitamin D, June 2008 Newsletter, p. 5-6
- Mayo Clinic 2010 research on Vitamin D and fNHL, September 2010 Newsletter, p. 14-16
- Vitamin D supplements and dosage considerations, February 2012 Newsletter, p. 10-18; October 2009 Newsletter, p. 7-9
- Researchers attempt to define optimal vitamin D level, September 2012 Newsletter, p.15-16
- Barriers in achieving optimal Vitamin D levels, June 2009 Newsletter, p. 4-9; May 2008 Newsletter, p. 6-9
- Fat solubility and supplementation, Article #3, p. 20,41
- “Vitamin D and Immunity: A Double-Edged Sword”, May 2010 Newsletter, p. 7-9
- Vitamin A may limit optimization of Vitamin D, March 2010 Newsletter, p. 14-15
- Vitamin D and sunlamps, Article #3, p.21-22
- Vitamin D and sunscreen, June 2010 Newsletter, p. 18
- Vitamin D and bathing, February 2010 Newsletter, p. 14
- Personal comments from Dr. Gabe Mirkin, May 2009 Newsletter, p. 13-14; May 2008 Newsletter, p. 2-6, September 2010 Newsletter, p. 16
Vitamin E
- Epigenetic anti-cancer effects of tocotrienols in vitamin E, Article #11, p.17
- “Vital Role of Full Spectrum Vitamin E”, March 2011 Newsletter, p. 12-13
- Vitamin E tocotrienols found to reduce damage from radiation scanning, July 2013 Newletter, p. 19-22
- Why the 2014 SELECT research results are compromised by use of synthetic vitamin E, March 2014 Newsletter, p. 16-18
- Vitamin E tocotrienols anti-cancer benefits, April 2009 Newsletter, p. 12-14
- Rice bran oil as source of tocotrienol component of Vitamin E, Article #3, p. 42; March 2011 Newsletter, p. 12-13
- Red palm oil as a full-spectrum source of Vitamin E, Article #7, p. 47; May 2011 Newsletter, p. 42-44, March 2011 Newsletter, p. 12-13; Article #3, p. 42-43; April 2009 Newsletter, p. 12-14
- Vitamin E needs to be taken with selenium, Article #3, p. 42
- Vitamin E and NF-Kappa B pathway, January 2008 Newsletter, p. 17-18
Vitamin K
- “Vitamin K2 Must Accompany Vitamin D: Here’s Why”, January 2014 Newsletter, p. 18-21
- Epigenetic anti-cancer effects of vitamin K-2, Article #11, p.19
- The importance of K-2 (menaquinone) and how to get it from dietary sources, March 2013 Newsletter, p. 18-20; February 2012 Newsletter, p. 25-27; Article #3, p. 52; November 2011 Newsletter, p. 20; September 2011 Newsletter, p. 18-19
- Green leafy vegetables as source of vitamin K-1, Article #3, p. 50
- Mayo Clinic research study, April 2010, May 2010 Newsletter, p. 13-14
Vorinostat, Article #6, p. 31-32; August 2012 Newsletter, p. 18-19
W
Walnuts, February 2012 Newsletter, p. 25; April 2011 Newsletter, p. 23
Warburg, Dr. Otto
- Summary description of the “Warburg Effect” and its importance in getting follicular lymphoma cells to die on their own, Article #10, p. 6-7
- Dr. Warburg’s contributions to understanding cancer causation, June 2010 Newsletter, p. 3-6
- Dr. Warburg’s theory about cancer and lack of effective mitochondrial function in cancer cells, Article #10, p. 12-14; November 2010 Newsletter, p.10
Watch and wait (see Dynamic Observation)
Weil, Dr. Andrew, March 2008 Newsletter, p. 17-18, May 2010 Newsletter, p. 17
Wheatgrass, February 2013 Newsletter, p. 16-17
Whey Protein
- Whey protein powders should be avoided by fNHL patients, Article #10, p. 26-27; June 2013 Newsletter, p. 13-14: Article #7, p. 43-44; December 2012 Newsletter, p. 12-13; June 2012 Newsletter, p. 17-19; Article #3, p. 54
Will to Live, Article #3, p. 45; April 2010 Newsletter, p. 21
X
Y
Yogurt
- Article #3, p. 51-52; April 2015 Newsletter, p. 21-23
- Fermented milk products a healthier choice than milk, May 2015 Newsletter, p. 22-23
- “Six Reasons Why Yogurt is Essential”, March 2015 Newsletter, p. 17-19
- Yogurt as source for probiotics and calcium, Article #11, p.13
- Information on making homemade yogurt, October 2013 Newsletter, p. 16-18
Z
Zevalin
- General information, Article #6, p.24; August 2012 Newsletter, p. 19-20
- Zevalin manufacturer requests removal of pre-treatment evaluation bioscan, February 2011 Newsletter, p. 13-14
- Significance of FDA approval, September 2009 Newsletter, p. 2-6
- Research comparing Zevalin and Bexxar, July 2008 Newsletter, p. 13-14
- 2008 Italian research study, April 2008 Newsletter, p. 7-8
- Reseach evaluating effectiveness, June 2010 Newsletter, p.12-13
Zinc, Article #3, p.40